id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-1067-0005,FDA,FDA-2013-D-1067,Guidance for Industry Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products-Content and Format,Other,Guidance,2014-12-11T05:00:00Z,2014,12,2014-12-11T05:00:00Z,2014-12-11T04:59:59Z,2024-11-12T05:33:20Z,,1,0,090000648196f9e7
FDA-2013-D-1067-0004,FDA,FDA-2013-D-1067,"Patient Counseling Information Section of Labeling for Human 
Prescription Drug and Biological Products--Content and Format; Guidance for Industry; Availability",Notice,Notice of Availability,2014-12-10T05:00:00Z,2014,12,2014-12-10T05:00:00Z,,2024-11-12T05:32:29Z,2014-28888,1,0,090000648196aa70
FDA-2013-D-1067-0001,FDA,FDA-2013-D-1067,Draft Guidance for Industry on Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products--Content and Format; Availability,Notice,Notice of Data Availability,2013-09-18T04:00:00Z,2013,9,2013-09-18T04:00:00Z,2013-11-19T04:59:59Z,2013-11-19T02:02:14Z,2013-22644,0,0,0900006481429d06
FDA-2013-D-1067-0002,FDA,FDA-2013-D-1067,Draft Guidance for Industry on Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products--Content and Format,Other,Guidance,2013-09-18T04:00:00Z,2013,9,2013-09-18T04:00:00Z,,2024-11-11T20:48:23Z,,1,0,090000648142a036